Literature DB >> 34209172

Molecular Landscape of Vulvar Squamous Cell Carcinoma.

Nuria Carreras-Dieguez1,2, José Guerrero3, Maria Teresa Rodrigo-Calvo3, Inmaculada Ribera-Cortada3, Isabel Trias3, Pedro Jares2,3, Ricardo López Del Campo3, Adela Saco3, Meritxell Munmany1, Lorena Marimon4, Melania Ferrando4, Naiara Vega3, Marta Del Pino1,2, Aureli Torné1,2, Jaume Ordi3,4, Natalia Rakislova3,4.   

Abstract

Vulvar squamous cell carcinoma (VSCC) is a rare malignancy with dual pathogenesis, Human papillomavirus (HPV)-associated and HPV-independent, with a poorly explored molecular landscape. We aimed to summarize the findings of the series analyzing molecular hallmarks of this neoplasm. In January 2021, we conducted a comprehensive literature search using Pubmed Medline and Scopus to identify publications focused on genomic profiling of VSCC. Observational studies, including both prospective and retrospective designs, evaluating molecular alterations in VSCC were deemed eligible. A total of 14 studies analyzing 749 VSCC were identified. The study series were heterogeneous in HPV testing and sequencing strategies, included small sets of tumors and cancer genes, and commonly lacked survival analysis. Only one extensive targeted next-generation sequencing-based study comprised a large cohort of 280 VSCC. The mutated genes, their number, and frequencies were highly variable between the series. Overall, TP53 and CDKN2A, followed by PIK3CA, HRAS, and PTEN, were the most frequently studied and mutated genes. Mutations involved in the PI3K/AKT/mTOR pathway, including TP53, HRAS, KRAS, and PIK3CA, have been consistently reported across the studies. However, the role of individual mutations or pathways in the development of VSCC remains unclear. In conclusion, heterogeneity and the small sample size of available molecular series contribute to a limited view of the molecular landscape of VSCC. Large-scale genome- or exome-wide studies with robust HPV testing are necessary to improve the molecular characterization of VSCC.

Entities:  

Keywords:  genomic landscape; molecular analysis; next generation sequencing; vulvar cancer; vulvar squamous cell carcinoma; whole-exome sequencing

Year:  2021        PMID: 34209172     DOI: 10.3390/ijms22137069

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  5 in total

1.  Advances in Gynecological Cancers.

Authors:  Michalis Liontos; Oraianthi Fiste; Flora Zagouri; Meletios-Athanasios Dimopoulos
Journal:  Int J Mol Sci       Date:  2022-05-31       Impact factor: 6.208

2.  Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma.

Authors:  Abeer M Salama; Amir Momeni-Boroujeni; Chad Vanderbilt; Marc Ladanyi; Robert Soslow
Journal:  Mod Pathol       Date:  2021-10-14       Impact factor: 8.209

3.  HPV-negative Penile Intraepithelial Neoplasia (PeIN) With Basaloid Features.

Authors:  José Guerrero; Isabel Trias; Luis Veloza; Marta Del Pino; Adriana Garcia; Lorena Marimon; Sherley Diaz-Mercedes; Maria T Rodrigo-Calvo; Silvia Alós; Tarek Ajami; Rafael Parra-Medina; Antonio Martinez; Oscar Reig; Maria J Ribal; Juan M Corral-Molina; Jaume Ordi; Inmaculada Ribera-Cortada; Natalia Rakislova
Journal:  Am J Surg Pathol       Date:  2022-03-17       Impact factor: 6.298

4.  Pathogenesis of Penile Squamous Cell Carcinoma: Molecular Update and Systematic Review.

Authors:  Inmaculada Ribera-Cortada; José Guerrero-Pineda; Isabel Trias; Luis Veloza; Adriana Garcia; Lorena Marimon; Sherley Diaz-Mercedes; José Ramon Alamo; Maria Teresa Rodrigo-Calvo; Naiara Vega; Ricardo López Del Campo; Rafael Parra-Medina; Tarek Ajami; Antonio Martínez; Oscar Reig; Maria J Ribal; Juan Manuel Corral-Molina; Pedro Jares; Jaume Ordi; Natalia Rakislova
Journal:  Int J Mol Sci       Date:  2021-12-27       Impact factor: 5.923

Review 5.  Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma.

Authors:  Hai-Long Li; Nian-Hua Deng; Xiu-Sheng He; Yue-Hua Li
Journal:  Biomark Res       Date:  2022-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.